In this study, we discovered that, amongst a general increase in cytokines and sol-CR expression in PBC patients (primarily ESPBC), the type II/III interferon system and soluble HVEM may play important roles in disease progression and response to UDC treatment. The gene discussed is TNFRSF14; the disease is primary biliary cholangitis.